Aleniglipron
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of ... developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results. References {{reflist GLP-1 receptor agonists Experimental diabetes drugs Organophosphine oxides Anilines Imidazoles Oxadiazoles Pyrazolopyridines Indoles 4-Fluorophenyl compounds Ureas Carboxamides Cyclopropanes Tetrahydropyrans ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]